National news media outlets nearly silent on potential Trump family self-dealing pharmaceutical scheme

Major cable and broadcast news outlets seem to have largely ignored a Wall Street Journal report that Donald Trump Jr. stands to potentially benefit financially from a deal between BlinkRx and the government-run TrumpRx pharmaceutical program. Apparently, neither The New York Times or The Washington Post covered the Journal’s findings either.

On September 30, President Donald Trump announced TrumpRx, a government-run platform scheduled to launch in 2026 that would funnel consumers to drug companies’ direct-sale websites — precisely the service BlinkRx announced it could help facilitate in August. Donald Trump Jr. joined the company’s board in February of this year, and also serves as a partner of the investment firm 1789 Capital, a “lead investor” in BlinkRx. According to the Wall Street Journal report, before the President’s TrumpRx reveal, a BlinkRx representative “told one drug company that BlinkRx could be involved with running the site on behalf of the Centers for Medicare and Medicaid Services.”

According to the Journal, BlinkRx has also organized a summit in December which will facilitate meetings between the country’s top drugmakers, feature “ ‘small group meetings’ with Treasury Secretary Scott Bessent, Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare and Medicaid Services Administrator Mehmet Oz and Food and Drug Administration Commissioner Marty Makary”, and “conclude with a dinner at the Executive Branch, an exclusive new club founded by Trump Jr. and his close friends.”